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We characterized the population of users of inhaled long-acting &-agonists in the region of Friuli-Venezia Giulia, 
in Italy, and assessed changes in asthma treatment and control after initiating long-acting &agonists. 
All residents using formoterol or salmeterol between 1992 and 1996 were identified in the regional Health 
Databases. Utilization rates of asthma medications and hospitalization rates for asthma were computed for the 
year before and after the date of the first long-acting p2-agonist prescription. 
There were 3803 users of formoterol and 20 054 users of salmeterol. Overall, 65% of users were older than 54 
years of age. All formoterol users and 86% of salmeterol users received their first prescription for the respective 
drug during the study period (new users). Among these new users, 50% had not received any asthma drug during 
the 4 months preceding the start of long-acting &agonist administration. Prior 1 yr utilization rates of asthma 
medications and hospitalization rates for asthma were greater among new users of long-acting j?z-agonists than 
among new users of salbutamol and xanthines. In addition, formoterol new users had higher prior use of asthma 
drugs than new users of salmeterol. One year prior hospitalization rates for asthma were also higher among 
formoterol than salmeterol new users with rate ratios of 1.7 (95% CI 1.3-2.2) for patients younger than 45 and 1.5 
(1.2-1.9) for older patients. Use of short-acting j&agonists, oral steroids and xanthines significantly declined after 
starting formoterol, whereas the use of inhaled steroids increased after the start of either formoterol or salmeterol. 
Asthma hospitalizations decreased by 32% in patients under age 45, by 43% in older patients, during the year 
following the start of formoterol, and by 15% and 24%, respectively, after the start of salmeterol. 
We conclude that long-acting &agonists were mainly prescribed to middle-aged and elderly patients and that 
formoterol appeared to be preferentially prescribed to patients with more severe asthma than salmeterol. Changes 
in asthma treatment and reduction in hospitalization rates for asthma after starting formoterol and salmeterol are 
compatible with an improvement in the control of asthma. 
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Introduction 
Formoterol and salmeterol are two inhaled long-acting pz- 
agonists indicated in the prophylaxis and treatment of 
bronchoconstriction in patients with reversible obstructive 
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airways disease. Formoterol can be differentiated from 
salmeterol by its faster onset of action, whereas duration of 
bronchodilation with the two agonists is similar. Clinical 
trials have shown that the addition of an inhaled long- 
acting &agonist to inhaled steroid treatment reduces the 
frequency of asthma symptoms and exacerbations, and the 
use of inhaled short-acting /&-agonists without worsening 
long-term control of asthma (l-4). Current guidelines 
recommend combining. long-acting &agonists with low 
dose inhaled steroids as an alternative to increasing the 
dose of inhaled steroids in the management of chronic 
persistent asthma (5). The role of long-acting /&-agonists in 
the treatment of chronic obstructive pulmonary disease 
(COPD) is not well established. However, some studies 
suggest that formoterol and salmeterol can improve both 
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lung function and control of symptoms in patients with Individual records from these databases can be linked using 
COPD (6-8). for each resident of the region a unique personal identifier. 
Although guidelines for asthma treatment are well 
established, no information is available on the use of 
long-acting &agonists in the general population. Inade- 
quate or under-use of other asthma drugs, such as inhaled 
steroids have been reported in a number of epidemiological 
studies (9,lO). 
STUDY POPULATION AND DEFINITIONS 
In this study we assessed the use of inhaled long-acting 
&agonists in the general population of Friuli-Venezia 
Giulia, in Italy, using information from the regional Health 
Database. We specifically characterized the population of 
users of long-acting fiz-agonists and assessed changes in 
asthma treatment and control after starting long-acting jz- 
agonist therapy. 
We identified all residents with a prescription for asthma 
medication recorded in the Outpatient Prescription Data- 
base between 1992 and 1996. Asthma drugs considered 
were those included in category R03 (anti-asthmatics) of 
the Anatomic Therapeutic Chemical Classification (Table 1) 
(11). Oral steroids were included as asthma medications 
only among residents who received any of the other asthma 
drugs. Ketotifene, classified as anti-histaminic, was con- 
sidered as an anti-asthma medication. 
Population and methods 
DATA SOURCE 
The region of Friuli-Venezia Giulia, in Northern Italy, 
maintains a number of computerized databases where 
information on the use of health care resources by the 1.2 
million residents of the region is regularly recorded. The 
Patient Identification Database contains individual demo- 
graphic and vital data which are continually updated for 
addresses, general practitioner changes and migration to 
and from the region. The Outpatient Prescription Database 
holds detailed individual information on all prescription 
medications dispensed in the pharmacies of the region, 
since 1991, to the residents covered by the National Health 
Service. Finally, the Hospital Services Database has 
recorded information on all admissions to regional public 
and private hospitals since 1985. Information includes 
admission and primary diagnosis and up to three addi- 
tional, discharge diagnoses, together with all relevant dates. 
We defined as users of inhaled long-acting &agonists all 
patients within the study population who received for- 
moterol or sahneterol at any time during the study period. 
In addition, we deiined as new users of inhaled long-acting 
l3z -agonists all patients with a code for receiving formoterol 
or salmeterol recorded for the first time in the database and 
who had a prescription history recorded for at least 1 year 
before the first long-acting &agonist prescription. The 
same definition was used to identify new users of 
salbutamol and xanthines. 
We defined hospitalization for asthma as any hospitaliza- 
tion with a primary discharge diagnosis of asthma accord- 
ing to the International Classification of Diseases, 9th 
Revision, Clinical Modification, codes 493.OU93.99 (12). 
ANALYSIS 
We computed utilization rates of asthma medications for 
the year before and after the first long-acting &-agonist 
prescription. Rates were calculated as the number of 
prescriptions per person-years of observation. We used 
TABLE 1. Distribution of users of asthma medications by age group in Friuli-Venezia Giulia, Italy,1992-1996* 
Group of age years 
Asthma medications <45 245 
n (%) n (%) 
Inhaled 
Oral 
Overall 
Short-acting fla-agonists 
Long-acting &agonists 
Anticholinergics 
Ipratroprium compounds 
Steroid compounds 
Steroids 
Crymoglycates 
Shortacting jz-agonists 
Xanthines 
Steroids 
Ketotifene 
Any asthma medication 
16 476 (50) 26 677 (36) 
4763 (15) 17 222 (23) 
893 (3) 4654 (6) 
1571 (5) 6609 (9) 
6113 (19) 12902 (17) 
16 738 (51) 30 090 (41) 
7415 (23) 4341 (6) 
3576 (11) 3274 (4) 
5404 (17) 48 125 (65) 
2551 (8) 10318 (14) 
1962 (6) 1343 (2) 
32 707 73953 
*The sum of users for individual drug classes is greater than the overall number of users because a patient could receive more 
than one type of drug during the study period 
utilization rate ratios to compare use of asthma medica- 
tions, the previous year between new users of long-acting 
Sz-agonists (formoterol and salmeterol) and new users of 
salbutamol and xanthines, and between new users of 
formoterol and new users of salmeterol. Similarly, rate 
ratios were used to compare the use of asthma medications 
during the year after and the year before starting formoterol 
and salmeterol. The same methodology was used to estimate 
and compare the rates of hospitalization for asthma. 
In order to assess the current use of asthma medications 
at the time of starting inhaled long-acting &-agonists, we 
additionally computed the proportion of new users of long- 
acting &agonists who were prescribed other asthma 
medications during the 4 month period preceding the start 
of formoterol and salmeterol. 
All the analysis were stratified into two groups. Those 
aged younger than 45 and those aged 45 or older. This 
allowed assessment of the use of long-acting flz-agonists in 
young patients who most probably used asthma drugs for 
asthma rather than COPD. Rate ratios are presented with 
95% confidence intervals (CJ). 
Results 
USE OF ASTHMA MEDICATIONS 
A total of 106 660 patients received asthma medications 
during the 5 year study period. The annual prevalence of 
use increased from 3.2% in 1992 to 4.3% in 1996. Most 
users (69%) were aged 45 years or older and 53% were 
women. The distribution of users of each asthma medica- 
tion is presented in Table 1. The drug class most widely 
used was inhaled steroids followed by inhaled short-acting 
l&-agonists among patients under 45 years, and xanthines 
followed by inhaled steroids among patients aged 45 or 
older. There were no major differences in the distribution of 
use between women and men. 
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USE OF INHALED LONG-ACTING ,&- 
AGONISTS 
Inhaled long-acting a-agonists were used by 21 985 
patients (Table 2). Of these, 3 803 (17%) used formoterol 
and 20 054 (91%) salmeterol. The overall annual prevalence 
nearly doubled from 0.5% in 1992 to 0.9% in 1996. The age 
distribution was similar between formoterol and salmeterol 
users, and between men and women (Table 2). Twenty two 
percent of users were younger than 45 years old, 27% were 
aged 45 to 64, and 51% were older than 64. 
NEW USERS OF INHALED LONG-ACTING 
&-AGONISTS 
All 3 803 formoterol users were new users (receiving their 
first prescription during the study period) and there were 17 
265 new salmeterol users. Among new formoterol users, 
55% of those younger than 45, and 66% of those aged 45 or 
older, received another asthma medication during the four 
months preceding the start of formoterol. The correspond- 
ing proportions among new salmeterol users were 35% and 
49%, respectively. Recent (prior 4 months) treatment with 
inhaled steroids was found in 29% of new formoterol users 
younger than 45 and 35% of those in the older age group. 
For salmeterol new users, these proportions were 15% and 
18 % , respectively. 
New users of long-acting &agonists had higher utiliza- 
tion of other asthma medications in the preceding year than 
new users of salbutamol (n = 32 848) and xanthines (n = 35 
621) (Table 3). In addition, utilization rates of asthma 
medications during the year before onset of long-acting flz- 
agonists were higher among new users of formoterol than 
among new users of salmeterol. The previous years 
utilization rate ratios, comparing formoterol to salmeterol, 
for new users younger than 45 were 2.1 (95% CI 2.tk2.2) 
for inhaled short-acting /?ragonists, 2.7 (95% CI 2.5-2.9) 
for inhaled steroids, and 2.2 (95% CI 1.9-2.5) for oral 
steroids. Rate ratios for patients aged 45 or older were 2.1 
TABLE 2. Age and sex distribution of users of inhaled long-acting &agonists* 
Formoterol 
Men Women 
Age group n (Oh) n (%) 
< 14 57 (3) 54 (3) 
15-24 139 (7) 94 (5) 
25-34 132 (7) 198 (11) 
35-44 138 (7) 163 (9) 
45-54 212 (11) 257 (14) 
55-64 379 (19) 338 (18) 
65-74 603 (31) 452 (24) 
>74 289 (15) 298 (16) 
Total 1949 1854 
*Some patients used both formoterol and salmeterol during the study period 
Salmeterol 
Men Women 
n (Oh) n (%) 
243 (2) 136 (1) 
532 (5) 506 (5) 
670 (7) 742 (7) 
576 (6) 721 (7) 
965 (10) 1140 (11) 
1636 (16) 1598 (16) 
3123 (31) 2646 (26) 
2252 (23) 2568 (26) 
9997 10 057 
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TABLE 3. Utilization rates and rate ratios of selected asthma medications in the year prior to onset of treatment with long- 
acting /Z&agonists compared to onset of treatment with salbutamol and xanthines, stratified by age 
Utilization rates* Rate ratio (95% CI) 
Age Prior asthma Long-acting Salbutamol Xanthines Long-acting &-agonists Long-acting &agonists 
(years) medication /.&-agonists versus salbutamol versus xanthines 
<45 Salbutamol 1.73 - 0.55 - 3.2 (3.0-3.3) 
Inhaled steroids 0.84 0.41 0.27 2.1 (1.9-2.2) 3.1 (2.9-3.3) 
Oral steroids 0.18 0.06 0.10 2.8 (2.5-3.1) 1.8 (16-2.0) 
Xanthines 0.53 0.09 - 5.6 (5.2-5.9) - 
245 Salbutamol 2.19 0.27 8.2 (8.0-8~4) 
Inhaled steroids 1.96 0.67 0.30 2.9 (2.8-3.0) 6.6 (64-6.7) 
Oral steroids 0.42 0.24 0.16 1.7 (16-1~8) 2.6 (2.5-2.7) 
Xanthines 3,95 2.15 - 1.8 (1.7-1.9) - 
*Number of prescriptions per person per year 
TABLE 4. Utilization rates and rate ratios of use of asthma medications one year after versus one year before the start of 
formoterol and salmeterol stratified by age 
Asthma medication 
Formoterol new users Salmeterol new users 
(n=3803) (n = 17 265) 
Utilization rates* Rate ratio Utilization rates* Rate ratio 
Before After after/before (95%CI) Before After after/before (95%CI) 
Age ~45 
Inhaled short-acting &agonists 2.99 2.05 O-68 (0.64-0.72) 1 a42 1.56 1.10 (l-06-1*14) 
Inhaled steroids 1.70 2.77 l-63 (1.53-1.73) 0.63 l-26 1.99 (1.89-2.08) 
Oral steroids 0.33 0.26 0.83 (0.70498) 0.14 0.23 1.63 (1.47-1.81) 
Xanthines 0.79 0.70 0.88 (O-8&0-98) 0.47 0.59 1.27 (1.20-1.35) 
Age245 
Inhaled short-acting &agonists 3.84 2.56 O-67 (0.65-0.69) 1.84 l-73 0.94 (0.92496) 
Inhaled steroids 4.21 5.01 1.19 (1.16-l-22) 1.47 2.19 1.49 (1.461.51) 
Oral steroids 1.06 1.06 1.00 (0.96-l-06) 0.28 0.43 l-50 (144-l-56) 
Xanthines 5.11 4.94 0.97 (0.95499) 3.70 4.09 l-11 (1.09-1.12) 
*Number or prescriptions per person per year 
(95% CI 2.09-2.14), 2.9 (95% CI 2.8-2.92), and 3.7 (95% 
CI 3.53.9), respectively. 
When we compared utilization rates of inhaled short- 
acting &agonists between the year after and the year prior 
to starting formoterol there was a decrease of 32% in both 
age groups. The use of inhaled steroids increased by 63% in 
patients under 45 and by 19% in those aged 45 or older 
(Table 4). Finally, a small decrease in the use of oral 
steroids and xanthines was observed in the younger age 
group, whereas use remained almost unchanged in the older 
patients. Among new salmeterol users, utilization rates of 
inhaled short-acting /&agonists increased by 10% in 
patients under 45 and decreased by 6% in those 45 or 
older. The use of inhaled steroids, oral steroids and 
xanthines increased in both age groups after starting 
salmeterol (Table 4). 
Hospitalization rates for asthma the previous year were 
higher among new users of inhaled long-acting &agonists 
than among new users of salbutamol and new users of 
xanthines. Hospitalization rate ratios were 3.6 (95% CI 
3.0-4.3) and 2.1 (95% CI 1.7-2.6), respectively, for patients 
under age 45, and 2.2 (95% CI 1.8-2.6) and 4.2 (95% CI 
3.5-5.0) for those aged 45 or older. New users of formoterol 
had higher previous hospitalization rates for asthma than 
new users of salmeterol, with a rate ratio of 1.7 (95% CI 
1.3-2.2) for patients under age 45 and 1.5 (95% CI 1.2-1.9) 
for older patients (Table 5). 
After starting formoterol, asthma hospitalization 
rates decreased by 32% in patients under 45 and 43% in 
those 45 or older (Table 5). For new salmeterol users, 
hospitalization rates decreased by 15% and 24%, respec- 
tively. 
USEOFINHALEDLONG-ACTING &AGONISTS 713 
TABLE 5. Hospitalizations for asthma one year before and one year after and rate ratios of asthma hospitalizations one year 
after compared to one year before starting formoterol and salmeterol 
New users Age 
Year before Year after Rate ratio (95% CI) 
Number* IR Number* IR after/before 
Formoterol <45 76 8.0 52 5.5 0.68 (0.48497) 
245 89 3.1 51 1.8 0.57 (0.41-0.81) 
Salmeterol <45 187 4.7 159 4.0 0.85 (0.69-1.05) 
245 284 2.1 217 1.6 0.76 (0.64-0.91) 
IR: Incidence rate per 100 person-years 
*Number of hospitalizations for asthma 
Discussion 
In this population-based study we described the character- 
istics of users of long-acting flz-agonists in the region of 
Friuli-Venezia Giulia, in Italy, using information recorded 
in the Regional Health Databases. Data on the use of 
asthma medications was based on the prescriptions issued 
within the National Health Service. The unique identifica- 
tion number of each resident in the region allowed record 
linkage among different databases. Although information 
in the Friuli-Venezia Giulia Health Databases is mainly 
recorded for administrative purposes, a number of studies 
have already shown that the high quality and validity of the 
data permits its use in pharrnaco-epidemiological research 
(13,14). 
The present study showed that long-acting &agonists 
were mainly used by middle aged and elderly patients, 
suggesting that a high proportion of users might sutler from 
chronic obstructive pulmonary disease. However, stratify- 
ing the analysis by age groups allowed us to specifically 
assess the use of long-acting &agonists in young patients 
who most probably used asthma drugs for asthma rather 
than COPD. Review of patients medical charts identified in 
other automated health database, has shown that the use of 
inhaled short-acting &agonists and}or inhaled steroids is a 
valid marker of asthma in young patients (15). 
A relevant finding in our study was the low use of inhaled 
steroids before starting therapy with inhaled long-acting p2- 
agonists. Among patients under age 45, only 29% of new 
formoterol new users and 15% of new sahneterol users were 
previously treated with inhaled steroids. According to 
current guidelines for the management of chronic asthma, 
these findings suggest an inadequate use of long-acting f12- 
agonists. It seems that in this population long-acting Bz- 
agonists were often used as first line regular therapy (about 
50% of new users did not receive any asthma drug during 
the prior 4 months), although they could also have been 
used intermittently in the prevention of nocturnal and 
exercise-induced asthma. The low use of inhaled steroids in 
this population agrees with results from the Italian centres 
participating in the European Community Respiratory 
Health Survey, where only 29% of patients 20 to 44 years 
old reporting current severe asthma were treated with 
inhaled steroids (16). Under-use of inhaled steroids and 
under-treatment of asthma in general have been reported in 
a number of epidemiological studies in different countries 
(9,10,17,18). As expected, our data suggest that new users 
of long-acting bz-agonists had a greater degree of asthma 
severity than new users of salbutamol and new users of 
xanthines, as indicated by the higher previous use of other 
asthma medications and the higher previous rates of 
asthma hospitalizations, which are very well established 
markers of chronic asthma severity (19,20). In addition, 
these two parameters were higher among new users of 
formoterol than among new users of salmeterol in both age 
groups suggesting that formoterol was preferentially pre- 
scribed to patients with more severe asthma. This selective 
prescribing (channelling) could be explained by the fact that 
formoterol was introduced on the market after salmeterol, 
and also by the faster onset of action of formoterol, 
complying with physicians search for a more rapid relief of 
symptoms for their more severe patients. Selective pre- 
scribing of specific inhaled short-acting j&agonists to more 
severe asthmatics has also been well documented in a 
number of studies (21,22). Changes in asthma treatment 
and reduction of hospitalization rates for asthma after 
starting long-acting j&agonists could point to a subsequent 
overall improvement in the control of asthma. This trend 
was particularly noted present among new formoterol users 
whose use of short-acting &agonists, oral steroids, and 
xanthines, and their hospitalization rates for asthma 
significantly declined after starting treatment with formo- 
terol. Some of these changes could be explained by the 
concomitant increase in the use of inhaled steroids observed 
after initiating long-acting /&agonists. This is supported by 
the results of an epidemiological study conducted in the 
U.S., in which use of inhaled steroids was associated with a 
significant decrease in the risk of hospitalization for 
asthma, especially in patients with severe asthma (23). 
Also, a recent clinical trial showed a reduction in the rates 
of asthma exacerbation over a one year period when 
formoterol was added to different dose regimens of inhaled 
steroids, with the highest reduction occurring in patients 
treated with the highest dose of steroids (2). 
A limitation of our study is that it was based on 
prescriptions information only and we could not assess 
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compliance with the asthma treatment. This could result in 
an over-estimation of the use of asthma medications in this 
population. Data from Northern Italy have shown that 
only 65% of patients prescribed asthma medications 
actually took all drug treatment prescribed, although this 
percentage increased to 74% when asthma symptoms 
worsened (16). Other limitations including the lack of 
information on treatment indications and on the actual 
prescribed daily dose of the asthma drugs, did not allow a 
more detailed analysis to be conduct. 
In summary, this study showed that long-acting fiz- 
agonists were preferentially prescribed to middle-aged and 
elderly patients with a higher degree of asthma severity than 
new users of other asthma medications, and that asthma 
appeared to be more severe among new users of formoterol 
than salmeterol. Changes in asthma treatment and reduc- 
tion of hospitalization rates for asthma after initiating long- 
acting &agonists are compatible with a subsequent 
improvement in the control of asthma. 
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